title: Successful treatment of refractory low grade duodenal lymphoma with rituximab, an anti-CD20 monoclonal antibody.
abstract: Duodenal lymphoma accounts for a small percentage of gastrointestinal tumors and has a very poor prognosis. The majority of patients have little or no cure with limited time of remission. Median survival is 5 to 10 years, and most patients die of lymphoma, its complications, or complications of therapy. We report a patient with lymphoma refractory to treatment with cyclophosphamide, vincristine, and prednisone, who was successfully treated with rituximab, a CD-20 monoclonal antibody.
authors.affiliation: Department of Internal Medicine, St. Joseph Mercy Hospital, Ann Arbor, Michigan 48195, USA.
authors.forename: Shazia
authors.initials: S
authors.lastname: Ahmed
authors.forename: Aman
authors.initials: A
authors.lastname: Singh
authors.forename: John
authors.initials: J
authors.lastname: Krauss
authors.forename: Tracey
authors.initials: T
authors.lastname: Wentz
authors.forename: Naresh T
authors.initials: NT
authors.lastname: Gunaratnam
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004379:Duodenal Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D000069283:Rituximab; D017211:Treatment Failure
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab